Kunlun Capital is an investment firm.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Kunlun Capital is a value-oriented and fundamentally driven family office. We do not manage external funds.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2021 | Danwang Medical | Series A | 18.6M |
4/2021 | EdiGene | Series B | 61.6M |
12/2021 | Zhongke Digital | Series A | - |
3/2022 | UniXell | Seed Round | 0 |
12/2021 | CirCode | Seed Round | 20M |
4/2022 | Ningbo Shanshan | Post-IPO Equity | 0 |
12/2021 | Circular Code Biology | Seed Round | 20M |
12/2020 | NeoCura | Series A | 38.2M |
3/2021 | Nice Tuan | Series D | 0 |
3/2022 | CellOrigin Biotech | Venture Round | 0 |
5/2022 | Hui-Gene Therapeutics | Series C | - |
8/2021 | UniXell | Angel Round | - |
3/2022 | Nutshell Therapeutics | Series A | 0 |
12/2021 | Zhongke Digital | Series A | - |
3/2021 | Biotheus | Series B | - |
5/2022 | Hui-Gene Therapeutics | Series C | - |
4/2022 | Ningbo Shanshan | Post-IPO Equity | 0 |
3/2022 | CellOrigin Biotech | Venture Round | 0 |
3/2022 | Nutshell Therapeutics | Series A | 0 |
3/2022 | UniXell | Seed Round | 0 |
12/2021 | Zhongke Digital | Series A | - |
12/2021 | Circular Code Biology | Seed Round | 0 |
12/2021 | CirCode | Seed Round | 0 |
10/2021 | Danwang Medical | Series A | 0 |
8/2021 | UniXell | Angel Round | - |
Name | Price |
---|
Name | Size | Announced Date |
---|